Webendoerfer, Maximilian
Konik, Margarethe
Zettler, Markus
Wienker, Johannes
Rawitzer, Josefine
Esser, Stefan
Kehrmann, Jan
Herrmann, Ken
Reinhardt, Hans Christian
Witzke, Oliver
Dolff, Sebastian
Funding for this research was provided by:
Gilead Sciences
AstraZeneca
Universitätsklinikum Essen
Article History
Received: 2 February 2024
Accepted: 5 March 2024
First Online: 23 March 2024
Declarations
:
: H.C.R. received consulting and lecture fees from AbbVie, AstraZeneca, Roche, Janssen-Cilag, Novartis, Vertex and Merck. H.C.R. received research funding from Gilead and AstraZeneca. H.C.R. is a co-founder of CDL Therapeutics GmbH. O.W. is a member of the Editorial Board of Infection. All remaining authors have no relevant financial or non-financial interests to disclose.
: No approval by the local ethics committee was necessary.
: The patient consented to participate in this case report.
: The patient consented to publish this case report.